Clinical trials: Peripheral Neuropathy, Secondary to Drugs or Chemicals
Breast Cancer, Peripheral Neuropathy, Secondary to Drugs or Chemicals
Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
The cause of Chemotherapy-Induced Peripheral Neuropathy (CIPN) is still unknown. An estimated 55-60% of patients will experience lasting symptoms affecting function for years post-treatment.
- Trial name
- NCT02239601
- Testing
- Physical Therapy
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- CancerCare Manitoba
Peripheral Neuropathy, Secondary to Drugs or Chemicals, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy.
- Conditions
- Peripheral Neuropathy, Secondary to Drugs or Chemicals, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Paclitaxel Induced Neuropathy
- Trial name
- EX-CIPN (NCT07399561)
- Testing
- Exercise Intervention, Usual Care
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- National Cancer Center, Korea
Peripheral Neuropathy, Secondary to Drugs or Chemicals
Peripheral Blood Biomarkers Associated With CIPN
The investigators are doing a research study that will teach us about the tingly pain that people develop when they get chemotherapy.
- Trial name
- NCT02661399
- Volunteers
- 100 people
- Sponsor
- St. Louis University